|
1
|
Lam SS, Ho ES, He BL, Wong WW, Cher CY, Ng
NK, Man CH, Gill H, Cheung AM, Ip HW, et al: Homoharringtonine
(omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute
myeloid leukemia. Sci Transl Med. 8:359ra1292016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferrara F and Schiffer CA: Acute myeloid
leukaemia in adults. Lancet. 381:484–495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Quintás-Cardama A, Santos FP and
Garcia-Manero G: Histone deacetylase inhibitors for the treatment
of myelodysplastic syndrome and acute myeloid leukemia. Leukemia.
25:226–235. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Papaemmanuil E, Gerstung M, Bullinger L,
Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F,
Bolli N, et al: Genomic classification and prognosis in acute
myeloid leukemia. N Engl J Med. 374:2209–2221. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rosenblat TL, McDevitt MR, Mulford DA,
Pandit-Taskar N, Divgi CR, Panageas KS, Heaney ML, Chanel S,
Morgenstern A, Sgouros G, et al: Sequential cytarabine and
alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195)
for acute myeloid leukemia. Clin Cancer Res. 16:5303–5311. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stein EM, DiNardo CD, Pollyea DA, Fathi
AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn
IW, et al: Enasidenib in mutant IDH2 relapsed or refractory acute
myeloid leukemia. Blood. 130:722–731. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Döhner H, Weisdorf DJ and Bloomfield CD:
Acute myeloid leukemia. N Engl J Med. 373:1136–1152. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Walter RB and Estey EH: Management of
older or unfit patients with acute myeloid leukemia. Leukemia.
29:770–775. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Löwenberg B and Rowe JM: Introduction to
the review series on advances in acute myeloid leukemia (AML).
Blood. 127:12016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Döhner H, Estey EH, Amadori S, Appelbaum
FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson
RA, et al: Diagnosis and management of acute myeloid leukemia in
adults: Recommendations from an international expert panel, on
behalf of the European LeukemiaNet. Blood. 115:453–474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wei AH and Tiong IS: Midostaurin,
enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring
new hope to AML. Blood. 130:2469–2474. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Burnett A, Wetzler M and Löwenberg B:
Therapeutic advances in acute myeloid leukemia. J Clin Oncol.
29:487–494. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Feldman EJ, Lancet JE, Kolitz JE, Ritchie
EK, Roboz GJ, List AF, Allen SL, Asatiani E, Mayer LD, Swenson C
and Louie AC: First-in-man study of CPX-351: A liposomal carrier
containing cytarabine and daunorubicin in a fixed 5:1 molar ratio
for the treatment of relapsed and refractory acute myeloid
leukemia. J Clin Oncol. 29:979–985. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lancet JE, Cortes JE, Hogge DE, Tallman
MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE,
Cooper M, et al: Phase 2 trial of CPX-351, a fixed 5:1 molar ratio
of cytarabine/daunorubicin, vs. cytarabine/daunorubicin in older
adults with untreated AML. Blood. 123:3239–3246. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stein EM and Tallman MS: Emerging
therapeutic drugs for AML. Blood. 127:71–78. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Besse L, Kraus M, Besse A, Bader J, Silzle
T, Mehrling T and Driessen C: The first-in-class alkylating HDAC
inhibitor EDO-S101 is highly synergistic with proteasome inhibition
against multiple myeloma through activation of multiple pathways.
Blood Cancer J. 7:e5892017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mehrling T and Chen Y: The alkylating-HDAC
inhibition fusion principle: Taking chemotherapy to the next level
with the first in class molecule EDO-S101. Anticancer Agents Med
Chem. 16:20–28. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu J, Qiu S, Ge Q, Wang Y, Wei H, Guo D,
Chen S, Liu S, Li S, Xing H, et al: A novel SAHA-bendamustine
hybrid induces apoptosis of leukemia cells. Oncotarget.
6:20121–20131. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Minotti G, Menna P, Salvatorelli E, Cairo
G and Gianni L: Anthracyclines: Molecular advances and
pharmacologic developments in antitumor activity and
cardiotoxicity. Pharmacol Rev. 56:185–229. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nishida Y, Mizutani N, Inoue M, Omori Y,
Tamiya-Koizumi K, Takagi A, Kojima T, Suzuki M, Nozawa Y, Minami Y,
et al: Phosphorylated Sp1 is the regulator of DNA-PKcs and DNA
ligase IV transcription of daunorubicin-resistant leukemia cell
lines. Biochim Biophys Acta. 1839:265–274. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Burden DA and Osheroff N: Mechanism of
action of eukaryotic topoisomerase II and drugs targeted to the
enzyme. Biochim Biophys Acta. 1400:139–154. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Murphy T and Yee KWL: Cytarabine and
daunorubicin for the treatment of acute myeloid leukemia. Expert
Opin Pharmacother. 18:1765–1780. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Drexler HG: Classification of acute
myeloid leukemias-a comparison of FAB and immunophenotyping.
Leukemia. 1:697–705. 1987.PubMed/NCBI
|
|
26
|
Zhao F, Sun X, Lu W, Xu L, Shi J, Yang S,
Zhou M, Su F, Lin F and Cao F: Synthesis of novel, DNA binding
heterocyclic dehydroabietylamine derivatives as potential
antiproliferative and apoptosis-inducing agents. Drug Deliv.
27:216–227. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zoi I, Karamouzis MV, Xingi E, Sarantis P,
Thomaidou D, Lembessis P, Theocharis S and Papavassiliou AG:
Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in
ERBB-2-positive breast carcinomas. Breast Cancer Res. 21:1322019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li X, Li C, Jin J, Wang J, Huang J, Ma Z,
Huang X, He X, Zhou Y, Xu Y, et al: High PARP-1 expression predicts
poor survival in acute myeloid leukemia and PARP-1 inhibitor and
SAHA-bendamustine hybrid inhibitor combination treatment
synergistically enhances anti-tumor effects. EBioMedicine.
38:47–56. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tewari M, Quan LT, O'Rourke K, Desnoyers
S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS and Dixit VM:
Yama/CPP32 beta, a mammalian homolog of CED-3, is a
CrmA-inhibitable protease that cleaves the death substrate
poly(ADP-ribose) polymerase. Cell. 81:801–809. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kaufmann SH, Desnoyers S, Ottaviano Y,
Davidson NE and Poirier GG: Specific proteolytic cleavage of
poly(ADP-ribose) polymerase: An early marker of
chemotherapy-induced apoptosis. Cancer Res. 53:3976–3985.
1993.PubMed/NCBI
|
|
31
|
Testa U and Riccioni R: Deregulation of
apoptosis in acute myeloid leukemia. Haematologica. 92:81–94. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Benito A, Silva M, Grillot D, Nuñez G and
Fernández-Luna JL: Apoptosis induced by erythroid differentiation
of human leukemia cell lines is inhibited by Bcl-XL. Blood.
87:3837–3843. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nuñez G and Clarke MF: The Bcl-2 family of
proteins: Regulators of cell death and survival. Trends Cell Biol.
4:399–403. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cheson BD and Rummel MJ: Bendamustine:
Rebirth of an old drug. J Clin Oncol. 27:1492–1501. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Garnock-Jones KP: Bendamustine: A review
of its use in the management of indolent non-Hodgkin's lymphoma and
mantle cell lymphoma. Drugs. 70:1703–1718. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pang B, de Jong J, Qiao X, Wessels LF and
Neefjes J: Chemical profiling of the genome with anti-cancer drugs
defines target specificities. Nat Chem Biol. 11:472–480. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pang B, Qiao X, Janssen L, Velds A,
Groothuis T, Kerkhoven R, Nieuwland M, Ovaa H, Rottenberg S, van
Tellingen O, et al: Drug-induced histone eviction from open
chromatin contributes to the chemotherapeutic effects of
doxorubicin. Nat Commun. 4:19082013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rogakou EP, Pilch DR, Orr AH, Ivanova VS
and Bonner WM: DNA double-stranded breaks induce histone H2AX
phosphorylation on serine 139. J Biol Chem. 273:5858–5868. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pilch DR, Sedelnikova OA, Redon C, Celeste
A, Nussenzweig A and Bonner WM: Characteristics of gamma-H2AX foci
at DNA double-strand breaks sites. Biochem Cell Biol. 81:123–129.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zou L and Elledge SJ: Sensing DNA damage
through ATRIP recognition of RPA-ssDNA complexes. Science.
300:1542–1548. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Reilly NM, Novara L, Di Nicolantonio F and
Bardelli A: Exploiting DNA repair defects in colorectal cancer. Mol
Oncol. 13:681–700. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen Y and Poon RY: The multiple
checkpoint functions of CHK1 and CHK2 in maintenance of genome
stability. Front Biosci. 13:5016–5029. 2008.PubMed/NCBI
|
